Short-Term Impact of Iron Deficiency in Different Subsets of Patients with Precapillary Pulmonary Hypertension from an Eastern European Pulmonary Hypertension Referral Center

References

• Galiè N, Humbert M, Vachiery JL, et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317.
   PubMed Web of Science ®Google Scholar
• Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi:10.1183/13993003.01913-2018
   PubMed Web of Science ®Google Scholar
• Jansa P, Jarkovsky J, Al-Hiti H, et al. A Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2014;14:(1):45. doi:10.1186/1471-2466-14-45
   PubMed Web of Science ®Google Scholar
• Chazova IY, Martynyuk TV, Valieva ZS, et al. Clinical and Instrumental Characteristics of newly diagnosed patients with various forms of pulmonary hypertension according to the Russian National Registry. Biomed Res Int. 2020;2020:6836973. doi:10.1155/2020/6836973
   PubMed Web of Science ®Google Scholar
• Kigitovica D, Sablinskis M, Sablinskis K, et al. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension incidence in Latvia in 2018. Eur J Intern Med. 2019;65:e9–e10. doi:10.1016/j.ejim.2019.04.022
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Foreman AJ, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant. 2015;34(3):356–361. doi:10.1016/j.healun.2014.09.016
   PubMed Web of Science ®Google Scholar
• Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator.0 and comparison With ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–337. doi:10.1016/j.chest.2019.02.004
   PubMed Web of Science ®Google Scholar
• Kanwar M, Raina A, Lohmueller L, et al. The use of risk assessment tools and prognostic scores in managing patients with pulmonary arterial hypertension. Curr Hypertens Rep. 2019;21(6):45. doi:10.1007/s11906-019-0950-y
   PubMed Web of Science ®Google Scholar
• Sitbon O, Nikkho S, Benza R, et al. Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension. Pulm Circ. 2020;10(4):2045894020962960. doi:10.1177/2045894020962960
   Web of Science ®Google Scholar
• Sonnweber T, Schneider EM, Nairz M, et al. Risk assessment in precapillary pulmonary hypertension: a comparative analysis. Respir Res. 2021;22(1):28. doi:10.1186/s12931-021-01624-z
   PubMed Web of Science ®Google Scholar
• Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017
   PubMed Web of Science ®Google Scholar
• Xiong W, Zhao Y, Xu M, et al. A modified risk score in one-year survival rate assessment of group 1 pulmonary arterial hypertension. BMC Pulm Med. 2018;18(1):161. doi:10.1186/s12890-018-0712-7
   PubMed Web of Science ®Google Scholar
• Deng X, Jin B, Li S, et al. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: a retrospective cohort study. Clin Respir J. 2019;13(11):693–699. doi:10.1111/crj.13076
   PubMed Web of Science ®Google Scholar
• Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL.0 risk score calculator, REVEAL Lite, for Use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337–346. doi:10.1016/j.chest.2020.08.2069
   PubMed Web of Science ®Google Scholar
• Ntiloudi D, Zanos S, Gatzoulis MA, et al. How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2019;17(1):11–18. doi:10.1080/14779072.2019.1550716
   PubMed Web of Science ®Google Scholar
• Rhodes CJ, Howard LS, Busbridge M, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011;58(3):300–309. doi:10.1016/j.jacc.2011.02.057
   PubMed Web of Science ®Google Scholar
• Ghio S, Fortuni F, Capettini AC, et al. Iron deficiency in pulmonary arterial hypertension: prevalence and potential usefulness of oral supplementation. Acta Cardiol. 2020;1–6.
   Web of Science ®Google Scholar
• Viethen T, Gerhardt F, Dumitrescu D, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol. 2014;175(2):233–239. doi:10.1016/j.ijcard.2014.04.233
   PubMed Web of Science ®Google Scholar
• Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol. 2006;48(2):356–365. doi:10.1016/j.jacc.2006.03.040
   PubMed Web of Science ®Google Scholar
• Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I. British committee for standards in haematology. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161(5):639–648. doi:10.1111/bjh.12311
   PubMed Web of Science ®Google Scholar
• Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity. Clin Chem. 2003;49(1):175–178. doi:10.1373/49.1.175
   PubMed Web of Science ®Google Scholar
• Sonnweber T, Nairz M, Theurl I, et al. The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension. PLoS One. 2018;13(8):e0203396. doi:10.1371/journal.pone.0203396
   PubMed Web of Science ®Google Scholar
• Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia. 2015;2015:763576. doi:10.1155/2015/763576
   PubMed Web of Science ®Google Scholar
• Steeds RP, Garbi M, Cardim N, et al.; 014–2016 EACVI Scientific Documents Committee;014–2016 EACVI Scientific Documents Committee. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017;18(11):1191–1204. doi:10.1093/ehjci/jew333.
   PubMed Web of Science ®Google Scholar
• Porter TR, Shillcutt SK, Adams MS, et al. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2015;28(1):40–56. doi:10.1016/j.echo.2014.09.009
   PubMed Web of Science ®Google Scholar
• Rosenkranz S, Preston IR. Right heart catheterisation: best practice and pitfalls in pulmonary hypertension. Eur Respir Rev. 2015;24(138):642–652. doi:10.1183/16000617.0062-2015
   PubMed Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117. doi:10.1164/ajrccm.166.1.at1102
   PubMed Web of Science ®Google Scholar
• Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428–1446. doi:10.1183/09031936.00150314
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57–65. doi:10.1161/CIRCULATIONAHA.113.004526
   PubMed Web of Science ®Google Scholar
• Pittrow D, Ghofrani HA, Opitz CF, Huscher D, Hoeper MM. Internationales, prospektives Register zur Erfassung der Initial- und Dauertherapie von Patienten mit pulmonaler Hypertonie (CompERA-XL) [International, prospective register for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL)]. Dtsch Med Wochenschr. 2009;134 Suppl 5(Suppl 5):S173–175. doi:10.1055/s-0029-1225318
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104–109. doi:10.1183/09031936.00092306
   PubMed Web of Science ®Google Scholar
• Baptista R, Meireles J, Agapito A, et al. Pulmonary hypertension in Portugal: first data from a nationwide registry. Biomed Res Int. 2013;2013:489574. doi:10.1155/2013/489574
   PubMed Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216–223. doi:10.7326/0003-4819-107-2-216
   PubMed Web of Science ®Google Scholar
• Rådegran G, Kjellström B, Ekmehag B, et al.; on behalf of SveFPH and SPAHR. Characteristics and survival of adult Swedish PAH and CTEPH patients000–2014. Scand Cardiovasc J. 2016;50(4):243–250. doi:10.1080/14017431.2016.1185532.
   PubMed Web of Science ®Google Scholar
• Escribano-Subias P, Blanco I, López-Meseguer M, et al. REHAP investigators. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596–603. doi:10.1183/09031936.00101211
   PubMed Web of Science ®Google Scholar
• Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–387. doi:10.1378/chest.09-1140
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030. doi:10.1164/rccm.200510-1668OC
   PubMed Web of Science ®Google Scholar
• Yu X, Luo Q, Liu Z, et al. Prevalence of iron deficiency in different subtypes of pulmonary hypertension. Heart Lung. 2018;47(4):308–313. doi:10.1016/j.hrtlng.2018.05.002
   PubMed Web of Science ®Google Scholar
• Marques-Alves P, Baptista R, Marinho da Silva A, Pêgo M, Castro G. Real-world, long-term survival of incident patients with pulmonary arterial hypertension. Rev Port Pneumol. 2017;23(3):124–131. doi:10.1016/j.rppnen.2017.01.006
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168(2):871–880. doi:10.1016/j.ijcard.2012.10.026
   PubMed Web of Science ®Google Scholar
• Radchenko GD, Zhyvylo IO, Sirenko YM. Analysis of pulmonary hypertension patient survival after treatment in referral center (data of first Ukrainian register). Pulm Circ. 2019;9(2):2045894019845604. doi:10.1177/2045894019845604
   Web of Science ®Google Scholar
• Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53(1):1801915. doi:10.1183/13993003.01915-2018
   PubMed Web of Science ®Google Scholar
• Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657–668. doi:10.1093/eurheartj/ehu385
   PubMed Web of Science ®Google Scholar
• Anker SD, Comin Colet J, Filippatos G, et al. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–2448. doi:10.1056/NEJMoa0908355
   PubMed Web of Science ®Google Scholar
• Ginzburg YZ. New diagnostic tools for delineating iron status. Hematology Am Soc Hematol Educ Program. 2019;2019(1):327–333. doi:10.1182/hematology.2019000035
   PubMedGoogle Scholar
• Sonnweber T, Pizzini A, Tancevski I, et al. Anaemia, iron homeostasis and pulmonary hypertension: a review. Intern Emerg Med. 2020;15(4):573–585. doi:10.1007/s11739-020-02288-1
   PubMed Web of Science ®Google Scholar
• Soon E, Treacy CM, Toshner MR, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax. 2011;66(4):326–332. doi:10.1136/thx.2010.147272
   PubMed Web of Science ®Google Scholar
• Ruiter G, Lankhorst S, Boonstra A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011;37(6):1386–1391. doi:10.1183/09031936.00100510
   PubMed Web of Science ®Google Scholar
• Xi Q, Liu Z, Liu W, Zhao Z, Luo Q, Huang Z. Chronic thromboembolic pulmonary hypertension is not associated with iron overload. Cardiovasc Pathol. 2015;24(2):76–79. doi:10.1016/j.carpath.2014.09.006
   PubMed Web of Science ®Google Scholar
• Van Empel VP, Lee J, Williams TJ, Kaye DM. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2014;23(3):287–292. doi:10.1016/j.hlc.2013.08.007
   PubMed Web of Science ®Google Scholar
• Rhodes CJ, Wharton J, Howard L, Gibbs JS, Vonk-Noordegraaf A, Wilkins MR. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J. 2011;38(6):1453–1460. doi:10.1183/09031936.00037711
   PubMed Web of Science ®Google Scholar